SESSION R.A. II (President and CEO) sold 0.3% of their position (28.61K shares) of TAYSHA GENE THERAPIES, INC. on the open market
Open‑market sale worth $20.1K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 6/26/2023ACC: 0000899243-23-016491
DirectorOfficer10% Owner· President and CEO
Since Sep 2020
-28.61K
Net shares
Net seller
$20.1K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
28.61K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−10.51K
Price / share
$0.70
Trade value
$7.38K
% of position
0.1%
6/22/2023
8.99M→8.98M
Common Stock
Direct
Shares
−18.10K
Price / share
$0.70
Trade value
$12.74K
% of position
0.2%
6/23/2023
8.98M→8.96M
Total
Net shares
−28.61K
Net value
-$20.12K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/22/2023 | S · Sale | −10.51K | $0.70 | $7.38K | 0.1% | 8.99M | 8.98M |
| Common Stock Direct | 6/23/2023 | S · Sale | −18.10K | $0.70 | $12.74K | 0.2% | 8.98M | 8.96M |
| Total | −28.61K | -$20.12K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
IndirectShares owned141.09K
Common Stock
IndirectShares owned141.09K
Total
282.18K indirect282.18K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 141.09K | Indirect |
| Common Stock | 141.09K | Indirect |
| Total | 282.18K | 282.18K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported